Cyxone's cyclotide study into inflammatory bowel disease starts at Medical University of Vienna
In response to interest from drug companies, Cyxone is to review whether cyclotides are effective against inflammatory bowel disease (IBD). The study was planned by the Medical University of Vienna and is now underway.Investigating the effects of cyclotides on IBD has become more relevant following Cyxone's discovery that the company's cyclotide T20K appears to accumulate in the intestine, the organ affected by IBD. Cyxone is following the IBD study with considerable interest. The study is expected to report in March this year. The company will then review the results of the study, and